ABSTRACT
Objective:To explore therapeutic effect of edaravone combined butylphthalide on acute ischemic stroke (AIS)and its safety.Methods:A total of 100 AIS patients treated in our hospital were selected.They were random-ly and equally divided into butylphthalide group and combined treatment group(received edaravone combined bu-tylphthalide).Both groups received routine treatment for five weeks all.Serum inflammatory cytokine levels,miR-222 expression and change of neurologic impairment before and after treatment,and therapeutic effect and inci-dence of complications after treatment were compared between two groups.Results:Compared with before treat-ment,after treatment,there were significant reductions in levels of high sensitive C reactive protein(hsCRP), tumor necrosis factor α(TNF-α)and interleukin 8(IL-8)and neurologic impairment score(NIS),and significant rise in miR-222 expression in two groups,P=0.001 all;compared with butylphthalide group after treatment,there were significant reductions in levels of hsCRP[(13.12 ± 2.56)mg/L vs.(10.02 ± 3.02)mg/L],TNF-α[(16.12 ± 4.18)μmol/L vs.(13.78 ± 3.24)μmol/L]and IL-8[(19.45 ± 5.98)μmol/L vs.(15.12 ± 3.29)μmol/L]and NIS [(19.12 ± 4.02)scores vs.(13.45 ± 3.17)scores],and significant rise in miR-222 expression[(1.21 ± 0.34)10-3 vs.(1.89 ± 0.41)10-3]in combined treatment group,P< 0.01 all.Total effective rate of combined treatment group was significantly higher than that of routine treatment group(96.00% vs.70.00%,P=0.001).No obvious adverse reactions were identified in either group.Conclusion:Edaravone combined butylphthalide possesses signifi-cant therapeutic effect on patients with acute ischemic stroke.It can effectively reduce levels of inflammatory fac-tors and improve neurologic function with satisfying safety.